The candidate is moving to long-awaited phase III trials — if successful, it would be the first new jab against the disease in more than 100 years. The candidate is moving to long-awaited phase III trials — if successful, it would be the first new jab against the disease in more than 100 years.
UK based cardiologist and anti-vaxxer Aseem Malhotra's visit to South Africa has raised public safety concerns among clinicians, scientists, and public health specialists in South Africa and beyond.
Tuberculosis kills 1.6 million a year the second deadliest infectious disease after COVID-19. Using immune cells and mRNA technology, scientists in South Africa are working on a new vaccine.